Greater Cannabis Company (GCAN) Cash & Equivalents (2017 - 2026)
Greater Cannabis Company's (GCAN) quarterly Cash & Equivalents came in at $1439.0 in Q1 2026, down 96.89% year-on-year from $46213.0 in Q1 2025, and up 76.56% quarter-over-quarter from $815.0 in Q4 2025.
Greater Cannabis Company (GCAN) Cash & Equivalents (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $1439.0 for Q1 2026.
- On a quarterly basis, Cash & Equivalents fell 96.89% year-over-year to $1439.0 in Q1 2026; TTM through Mar 2026 was $1439.0, a 96.89% decrease from a year earlier, with the FY2025 full-year figure at $815.0, down 98.58% from the prior year.
- Cash & Equivalents improved to $1439.0 in Q1 2026 per GCAN's latest filing, from $815.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $311197.0 in Q2 2022 and bottomed at $815.0 in Q4 2025.
- The 5-year median for Cash & Equivalents is $62282.0 (2024), against an average of $108819.7.
- Across the five-year window, Cash & Equivalents decreased 22.64% in 2023 and tumbled 98.58% in 2025, its largest moves.
- Year by year, Cash & Equivalents stood at $270030.0 in 2022, then slumped by 38.21% to $166859.0 in 2023, then sank by 65.62% to $57368.0 in 2024, then tumbled by 98.58% to $815.0 in 2025, then surged by 76.56% to $1439.0 in 2026.
- Per Business Quant, the three latest GCAN Cash & Equivalents figures stand at $1439.0 (Q1 2026), $815.0 (Q4 2025), and $21355.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | 1,439.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,439.00 |
| Dec 31, 2025 | 815.00 |
| Sep 30, 2025 | 21,355.00 |
| Jun 30, 2025 | 26,712.00 |
| Mar 31, 2025 | 46,213.00 |
| Dec 31, 2024 | 57,368.00 |
| Sep 30, 2024 | 62,282.00 |
| Jun 30, 2024 | 80,316.00 |
| Mar 31, 2024 | 129,323.00 |
| Dec 31, 2023 | 166,859.00 |
| Jun 30, 2023 | 240,747.00 |
| Dec 31, 2022 | 270,030.00 |
| Jun 30, 2022 | 311,197.00 |
| Dec 31, 2021 | 377,520.00 |
| Sep 30, 2021 | 456,358.00 |
| Jun 30, 2021 | 528,930.00 |
| Mar 31, 2021 | 316,722.00 |
| Dec 31, 2020 | 112,953.00 |
| Sep 30, 2020 | 178,632.00 |
| Jun 30, 2020 | 228,518.00 |